Top

Published in:

01-09-2021 | Breast Cancer | ASO Author Reflections

ASO Author Reflections: Postmastectomy Radiotherapy for Breast Cancer Patients After Neoadjuvant Chemotherapy, by Molecular Subtype

Authors: Jia-Chun Ma, MB, Xiao-Rong Zhong, MD, Ting Luo, MD, Lei Liu, MD

Published in: Annals of Surgical Oncology | Issue 9/2021

Excerpt

According to the National Comprehensive Cancer Network (NCCN) guidelines, postmastectomy radiotherapy (PMRT) for breast cancer patients after neoadjuvant chemotherapy (NAC) should be based on maximal stage from pre-chemotherapy tumor characteristics and/or pathological stage.¹ Retrospective analyses provided evidence for benefit of PMRT only for selected patients (patients presenting with clinical stage III disease and with four or more positive nodes) after NAC;² however, no data from randomized prospective trials are available to investigate which breast cancer patients need PMRT after NAC. There are great controversies surrounding this question. Nevertheless, molecular subtypes may influence the benefits of PMRT.³ Is molecular subtype a key predictive factor for locoregional recurrence (LRR) in patients receiving PMRT after NAC? …

Gradishar WJ, Anderson BO, Abraham J, et al. Breast cancer, Version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(4):452–78.CrossRef

Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004;22(23):4691–9.CrossRef

Scheer AS, Zih FS, Maki E, Koch CA, McCready DR. Post-mastectomy radiation: should subtype factor into the decision? Ann Surg Oncol. 2016;23(8):2462–70.CrossRef

Ma JC, Zhong XR, Luo T, et al. The effect of postmastectomy radiotherapy on breast cancer patients after neoadjuvant chemotherapy by molecular subtype. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-020-09523-1.CrossRefPubMed

Goodman CR, Seagle BL, Kocherginsky M, Donnelly ED, Shahabi S, Strauss JB. 21-Gene recurrence score assay predicts benefit of post-mastectomy radiotherapy in T1–2 N1 breast cancer. Clin Cancer Res. 2018;24(16):3878–87.CrossRef

Title: ASO Author Reflections: Postmastectomy Radiotherapy for Breast Cancer Patients After Neoadjuvant Chemotherapy, by Molecular Subtype
Authors: Jia-Chun Ma, MB
Xiao-Rong Zhong, MD
Ting Luo, MD
Lei Liu, MD
Publication date: 01-09-2021
Publisher: Springer International Publishing
Keywords: Breast Cancer
Breast Cancer
Radiotherapy
Cytostatic Therapy
Published in: Annals of Surgical Oncology / Issue 9/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-020-09555-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

ASO Author Reflections: Postmastectomy Radiotherapy for Breast Cancer Patients After Neoadjuvant Chemotherapy, by Molecular Subtype

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2021

Metaplastic Breast Carcinoma and Other Triple-Negative Subtype Breast Cancers: Which Is Worst?

Radial Scars and Complex Sclerosing Lesions of the Breast: Prevalence of Malignancy and Natural History Under Active Surveillance

Response to Letter to the Editor: “Omitting Sentinel Lymph Node Biopsy in Elderly Patients: A Lost Opportunity?” by Todd Tuttle et al.

Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators

ASO Author Reflections: “High-Risk” Lesions of the Breast: Low Risk of Cancer, High Risk of Overtreatment

ASO Author Reflections: Locoregional Therapy in De Novo Bone-Only Metastatic Breast Cancer Provides Survival Advantage Regardless of Therapy Sequencing